SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 8,650,000 shares, a decrease of 11.8% from the January 31st total of 9,810,000 shares. Based on an average daily volume of 2,700,000 shares, the short-interest ratio is presently 3.2 days.

SELLAS Life Sciences Group Price Performance

Shares of SELLAS Life Sciences Group stock opened at $1.19 on Friday. SELLAS Life Sciences Group has a one year low of $0.77 and a one year high of $1.84. The stock’s 50-day moving average is $1.18 and its 200 day moving average is $1.18. The firm has a market cap of $83.75 million, a price-to-earnings ratio of -1.72 and a beta of 2.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SLS. Brooklyn FI LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter valued at approximately $677,000. Anson Funds Management LP boosted its holdings in shares of SELLAS Life Sciences Group by 50.2% in the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company’s stock worth $1,240,000 after acquiring an additional 398,431 shares during the period. Northern Trust Corp boosted its holdings in shares of SELLAS Life Sciences Group by 33.6% in the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company’s stock worth $140,000 after acquiring an additional 33,878 shares during the period. Geode Capital Management LLC boosted its stake in SELLAS Life Sciences Group by 21.2% during the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company’s stock valued at $763,000 after buying an additional 128,355 shares during the period. Finally, Opus Capital Group LLC boosted its stake in SELLAS Life Sciences Group by 5.5% during the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company’s stock valued at $248,000 after buying an additional 12,400 shares during the period. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.